Crinetics Pharmaceuticals Inc.

121 articles about Crinetics Pharmaceuticals Inc.

• Crinetics Pharmaceuticals to Participate in Upcoming November 2023 Investor Conferences

  11/20/2023

  Crinetics Pharmaceuticals, Inc. announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35th Annual Healthcare Conference in New York City.

• Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 10, 2023

  11/10/2023

  Crinetics Pharmaceuticals, Inc. announced that on November 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/7/2023

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2023.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 10, 2023

  10/10/2023

  Crinetics Pharmaceuticals, Inc. announced that on October 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

  9/20/2023

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023.

• Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - September 13, 2023

  9/13/2023

  Crinetics Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 11,441,648 shares of its common stock at a price to the public of $30.59 per share.

• Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - September 11, 2023

  9/11/2023

  Crinetics Pharmaceuticals, Inc. announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 11, 2023

  9/11/2023

  Crinetics Pharmaceuticals, Inc. announced that on September 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 191,107 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• 

  Crinetics Aces Phase III in Rare Disease Acromegaly with Once-Daily Pill

  9/11/2023

  The California pharma is building up to its first-ever approval with promising late-stage data for its once-daily investigational acromegaly pill paltusotine, an alternative to the injectable standard of care.

• Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

  9/10/2023

  Crinetics Pharmaceuticals, Inc. announced that paltusotine, an oral, once-daily investigational compound, achieved positive results by meeting the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1 study.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 10, 2023

  8/10/2023

  Crinetics Pharmaceuticals, Inc. announced that on August 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 150,600 shares of its common stock to seven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/8/2023

  Crinetics Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.

• Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly

  7/31/2023

  Crinetics Pharmaceuticals, Inc. announced that it will host a Key Opinion Leader webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital, who will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 10, 2023

  7/10/2023

  Crinetics Pharmaceuticals, Inc. announced that on July 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 323,600 shares of its common stock to 10 new non-executive employees under the Crinetics Pharmaceuticals, Inc.

• New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

  6/21/2023

  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented efficacy, safety and patient-reported outcome (PRO) data at ENDO 2023 for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for the treatment of acromegaly.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 12, 2023

  6/12/2023

  Crinetics Pharmaceuticals, Inc. announced that on June 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 331,800 shares of its common stock to 14 new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Crinetics to Highlight Broad Pipeline at ENDO 2023

  6/9/2023

  Crinetics Pharmaceuticals, Inc. announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 10, 2023

  5/10/2023

  Crinetics Pharmaceuticals, Inc. announced that on May 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 295,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

• Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/4/2023

  Crinetics Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023.

• Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 10, 2023

  4/10/2023

  Crinetics Pharmaceuticals, Inc. announced that on April 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 311,700 shares of its common stock to 15 new non-executive employees under the Crinetics Pharmaceuticals, Inc.